Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Trial of Fast vs Slow Prednisone Taper in Giant Cell Arteritis
2024-518653-41-00Phase 3Authorised
- Sponsor
- CHU Caen Normandie
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone in giant cell arteritis (GCA) (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Complete remission without relapse at week 52 (per arm). Planned start Nov 2024; status: authorised.
02
Drugs
prednisone
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2024-518653-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518653-41-00.